iBio, Inc. (IBIO)
NASDAQ: IBIO · Real-Time Price · USD
1.630
-0.080 (-4.68%)
At close: Apr 28, 2026, 4:00 PM EDT
1.660
+0.030 (1.84%)
Pre-market: Apr 29, 2026, 4:00 AM EDT
iBio, Inc. Revenue
iBio, Inc. had revenue of $300.00K in the twelve months ending December 31, 2025, down -20.00% year-over-year. In the fiscal year ending June 30, 2025, iBio, Inc. had annual revenue of $400.00K with 77.78% growth.
Revenue (ttm)
$300.00K
Revenue Growth
-20.00%
P/S Ratio
196.38
Revenue / Employee
$15,000
Employees
20
Market Cap
58.91M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cue Biopharma | 27.47M |
| Metagenomi Therapeutics | 25.21M |
| MindWalk Holdings | 20.70M |
| BeyondSpring | 1.88M |
| ImageneBio | 800.00K |
| MediciNova | 409.66K |
IBIO News
- 20 days ago - iBio, Inc. Transcript: Status update - Transcripts
- 21 days ago - iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia - GlobeNewsWire
- 6 weeks ago - iBio, Inc. Transcript: Study update - Transcripts
- 6 weeks ago - iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) - GlobeNewsWire
- 7 weeks ago - iBio, Inc. Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss - GlobeNewsWire
- 2 months ago - iBio, Inc. Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference - Transcripts
- 2 months ago - iBio to Participate in Upcoming Investor Conferences - GlobeNewsWire